An observational study in Dyslipidemia, sponsored by AstraZeneca. Completed at 15 sites in Bulgaria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-09-10.
Sponsored by AstraZeneca · Observational
The purpose of this study is to establish the proportion of Bulgarian patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Fourth Joint European Task Force guidelines.
1,073 studies on the registry are indexed under Dyslipidemias; 158 are open to participants now.
This study's enrollment of 2,500 is above the median of 600 across 204 observational studies indexed under Dyslipidemias.
Browse Dyslipidemias studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Primary care clinic
Exclusion Criteria:
Patients with dyslipidemia on lipid lowering therapy
The number and percentage of patients achieving the LDL-C goals, according to the Fourth Joint European Task Force guidelines
Time frame: 6 months - one visit only, no follow-up visits
The number and percentage of subjects achieving the LDL-C goals, according to the Fourth Joint European Task Force guidelines for several subject subsets
Time frame: 6 months - one visit only, no follow-up visits
The number and percentage of subjects achieving LDL-C goals according to the NCEP ATP III / 2004 updated 2004 NCEP ATP III guidelines, overall and for several subject subsets
Time frame: 6 months - one visit only, no follow-up visits
The number and percentage of subjects achieving the non HDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III/national guidelines [<130mg/dL (3,37mmol/L)], in the following sub-population: patients with fasting triglycerides >200 mg/dL
Time frame: 6 months - one visit only, no follow-up visits
This study is completed, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca